3.68
-0.18 (-4.72%)
| Penutupan Terdahulu | 3.86 |
| Jumlah Dagangan | 4,171 |
| Harga / Jualan (P/S) | 1.37 |
| Harga / Buku (P/B) | 0.560 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -991.41% |
| EPS Cair (TTM) | -33.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -76.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 52.79% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | -57.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.68 M |
| Pulangan Atas Aset (ROA TTM) | -34.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -83.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Bolt Biotherapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.83 |
|
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.26% |
| % Dimiliki oleh Institusi | 46.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Board Of Trustees Of The Leland Stanford Junior University | 30 Jun 2026 | 35,977 |
| Nan Fung Group Holdings Ltd | 30 Jun 2026 | 5,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |